– An announcement on the present status of the development of stem cell therapeutics, US clinical results, etc.
– Introduction of global strategy for CARTISTEM® & PNEUMOSTEM®
MEDIPOST announced on March 31 that it will participate in the Bio USA (BIO International Convention 2019) in Philadelphia, USA for four days from June 3 to 6.
Bio USA held the world’s largest bio event organized annually by the Biotechnology Innovation Organization since 1993, and is expected more than 16,000 attendees across 74 countries this year.
In the Company Presentation to be held on the 5th, MEDIPOST plans to announce the development and approval status of its stem cell therapeutic pipeline and clinical trial results in Korea and the US.
MEDIPOST’s knee osteoarthritis treatment CARTISTEM® completed the US clinical phase 1/2a last year, while the bronchopulmonary dysplasia treatment PNEUMOSTEM® completed the US phase 1/2 clinical trial in January this year.
A company representative said, “CARTISTEM® and PNEUMOSTEM® are aiming to license out for the global market and will discuss the next phase of clinical trials with the US FDA within the year.”
In addition, he said that “CARTISTEM®, which has accumulated domestic sales of more than 12,000 vials as of the end of May 2019, received great interest in the global cell therapy market,” and that “it will be a good opportunity to introduce the products and commercialization strategies.”